title: Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn.
abstract: Hemolytic disease of the fetus and newborn (HDFN) affects 3/100 000 to 80/100 000 patients per year. It is due to maternal blood group antibodies that cause fetal red cell destruction and in some cases, marrow suppression. This process leads to fetal anemia, and in severe cases can progress to edema, ascites, heart failure, and death. Infants affected with HDFN can have hyperbilirubinemia in the acute phase and hyporegenerative anemia for weeks to months after birth. The diagnosis and management of pregnant women with HDFN is based on laboratory and radiographic monitoring. Fetuses with marked anemia may require intervention with intrauterine transfusion. HDFN due to RhD can be prevented by RhIg administration. Prevention for other causal blood group specificities is less studied.
authors.affiliation: Seattle Children's Hospital, Seattle, WA; University of Washington, Seattle, WA; and Bloodworks NW, Seattle, WA.
authors.forename: Meghan
authors.initials: M
authors.lastname: Delaney
authors.affiliation: Seattle Children's Hospital, Seattle, WA; University of Washington, Seattle, WA; and.
authors.forename: Dana C
authors.initials: DC
authors.lastname: Matthews
mesh_terms: D000740:Anemia / Q000150:complications; D001789:Blood Group Antigens; D001805:Blood Transfusion, Intrauterine; D004899:Erythroblastosis, Fetal / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D004912:Erythrocytes / Q000166:cytology; D005260:Female; D005333:Fetus / Q000502:physiology; D006801:Humans; D006932:Hyperbilirubinemia / Q000150:complications; D007231:Infant, Newborn; D007518:Isoantibodies / Q000097:blood; D009035:Mothers; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System
chemical_list: D001789:Blood Group Antigens; D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System